TBI

Danaher Launches Collaboration with Johns Hopkins University Aiming to Improve Neurological Diagnosis

Retrieved on: 
星期四, 五月 9, 2024
Johns Hopkins University, Traumatic brain injury, MSN, Danaher Corporation, BSN, Risk, DHR, Blood, Johns Hopkins, MD, Doctor of Philosophy, Research, TBI, Brain damage, Beacon, Patient, RN, Diagnosis, Brain, Biomarker, Emergency medicine, Medical imaging

This approach could potentially be adapted for diagnosis of other neurological conditions.

Key Points: 
  • This approach could potentially be adapted for diagnosis of other neurological conditions.
  • WASHINGTON, May 9, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator ("Danaher"), today launched a collaboration with Johns Hopkins University aiming to develop new methods for diagnosing mild TBI.
  • As part of the Danaher Beacons program, researchers at Johns Hopkins University will leverage technology from Beckman Coulter Diagnostics, a Danaher subsidiary and leader in clinical diagnostics, to potentially establish correlations between a new biomarker panel and clinical outcomes.
  • The Danaher Beacon for Brain Injury Diagnostics is the sixth collaboration in the Danaher Beacons program, which funds product-driven scientific research with globally recognized academic investigators.

Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia

Retrieved on: 
星期二, 五月 7, 2024
Contract research organization, Brain, Traumatic brain injury, NCE, Common, Food and Drug Administration, Therapeutic Goods Administration, Food, Partnership, Science, TBI, Concussion, Incidence, Patient, CTE, Head Injuries, DSM-IV codes, Chronic traumatic encephalopathy, Clinical trial, European Medicines Agency, Traffic, Pharmaceutical industry

This trial aims to evaluate Oragenics' lead drug candidate, ONP-002, for mild Traumatic Brain Injury (TBI), commonly known as concussion.

Key Points: 
  • This trial aims to evaluate Oragenics' lead drug candidate, ONP-002, for mild Traumatic Brain Injury (TBI), commonly known as concussion.
  • An Oragenics Phase I clinical trial, recently completed in Australia under the management of Avance Clinical, demonstrated that ONP-002 is safe and well-tolerated.
  • "Concussion remains a significant unmet medical need," said Dr. Jorgen Mould, Senior Director of Scientific and Regulatory Services at Avance Clinical.
  • Michael Redmond, President of Oragenics, added, "Our collaboration with Avance Clinical during the Phase I trial was instrumental, and we are confident in their ability to execute an effective Phase II trial that will pave the way for future treatment protocols for concussion."

Chrysalis BioTherapeutics Selected to Present at Respiratory Innovation Summit

Retrieved on: 
星期一, 五月 6, 2024
Biotechnology, FDA, Health, Pharmaceutical, Other Science, Research, Infectious Diseases, Hospitals, Science, COVID-19, Clinical Trials, University, Pupa, Summit, COVID, UTHealth School of Dentistry, NIH, Abstract, Human services, UTMB, Development, TBI, Therapy, Patient, RIS, Diagnosis, White lung, American Thoracic Society

Chrysalis BioTherapeutics today announced it was selected to participate in the 2024 Respiratory Innovation Summit (RIS) at the American Thoracic Society Meeting in San Diego.

Key Points: 
  • Chrysalis BioTherapeutics today announced it was selected to participate in the 2024 Respiratory Innovation Summit (RIS) at the American Thoracic Society Meeting in San Diego.
  • This year, Chrysalis was selected as one of six “Critical Care Therapeutic Innovator” companies for oral presentation at the Summit.
  • “To be selected to present at the Respiratory Summit is a great honor for Chrysalis and confirms that experts in this field recognize the potential of TP508 (Chrysalin™) to prevent progression of acute lung injury,” said Dr. Darrell Carney, Chrysalis CEO.
  • Chrysalis BioTherapeutics is currently seeking investors and pharma partners for pulmonary and other indications including TBI, radiation therapy and mitigation chronic pulmonary diseases.

TrueBlue Reports First Quarter 2024 Results

Retrieved on: 
星期一, 五月 6, 2024
Professional Services, Business, Apps, Applications, Technology, Human Resources, Consulting, Outsourcing Business, TBI, Webcast, Work

TrueBlue (NYSE:TBI) today announced its first quarter results for 2024.

Key Points: 
  • TrueBlue (NYSE:TBI) today announced its first quarter results for 2024.
  • “As anticipated, market conditions have remained challenging and we continue to manage through the current cycle with agility and discipline,” said Taryn Owen, President and CEO of TrueBlue.
  • Management will discuss first quarter 2024 results on a webcast at 2:00 p.m. PT (5:00 p.m.
  • The webcast can be accessed on the Investor Relations section of the TrueBlue website: investor.trueblue.com .

GREENSTEIN & MILBAUER, LLP FILES MULTIPLE TRUCK ACCIDENT LAWSUITS

Retrieved on: 
星期二, 四月 30, 2024
Accident, Burns, LLP, Supreme court, Pepsi, Neck, Death, Fracture, Injury, Amazon, TBI, Amputation, Internal bleeding, Crash, Wound, Head, Traumatic brain injury, Tetraplegia, Road

NEW YORK, April 30, 2024 /PRNewswire/ -- Greenstein & Milbauer, LLP, a personal injury law firm based in New York City ( www.nyclawfirm.com ) has filed multiple truck accident lawsuits..

Key Points: 
  • NEW YORK, April 30, 2024 /PRNewswire/ -- Greenstein & Milbauer, LLP, a personal injury law firm based in New York City ( www.nyclawfirm.com ) has filed multiple truck accident lawsuits..
  • Robert Greenstein, a partner at Greenstein & Milbauer, LLP, states, "Accidents involving large trucks are much more complicated than many other traffic accidents.
  • fatal truck accidents)
    If you were injured in a truck accident, you can recover compensation for your injuries and damages.
  • The New York City truck accident lawyers at Greenstein & Milbauer, LLP, can help you recover the compensation you deserve.

TrueBlue's PeopleScout Unveils "Connect More"™ Brand Promise

Retrieved on: 
星期二, 四月 30, 2024
Acceleration, AI, EVP, Communication, Partnership, TBI, Digital, Automation, Clinic, Work, Digital transformation, Acquisition, Workforce, TrueBlue, Friction, Organization, Connect, Amplifier, Creative industries

TACOMA, Wash., April 30, 2024 /PRNewswire/ -- TrueBlue (NYSE: TBI), a leading provider of specialized workforce solutions, today announced that its global talent solutions brand, PeopleScout, has undergone a strategic brand refresh. PeopleScout's new brand promise, "Connect More", and refreshed visual identity convey the importance of meaningful connections between employers and critical talent in the changing world of work.

Key Points: 
  • TACOMA, Wash., April 30, 2024 /PRNewswire/ -- TrueBlue (NYSE: TBI), a leading provider of specialized workforce solutions, today announced that its global talent solutions brand, PeopleScout , has undergone a strategic brand refresh.
  • PeopleScout's new brand promise, "Connect More", and refreshed visual identity convey the importance of meaningful connections between employers and critical talent in the changing world of work.
  • "PeopleScout's 'Connect More' brand promise emphasizes the importance of these connections across the talent spectrum, furthers our mission to connect people and work, and underscores the important difference the right talent can make for our clients."
  • Talent Advisory: With one of the industry's largest in-house talent advisory teams, PeopleScout delivers fresh perspectives and innovative solutions to complex talent acquisition challenges.

Caesars Entertainment, Inc. Appoints Kim Harris Jones to Board of Directors

Retrieved on: 
星期一, 四月 29, 2024
Casino, Gaming, Entertainment, Lodging, Travel, Black Enterprise, University, Caesars Entertainment, United Rentals, Mondelez International, Consortium, TBI, CZR, CPA, General Motors, Senior, Education minister, FOSL, Fossil Group, MBA, TrueBlue, CFO (magazine), Woman, Management

With a track record of strategic corporate leadership as both an executive and a board member, Harris Jones will bring a unique perspective and in-depth experience to the Caesars Entertainment Board of Directors.

Key Points: 
  • With a track record of strategic corporate leadership as both an executive and a board member, Harris Jones will bring a unique perspective and in-depth experience to the Caesars Entertainment Board of Directors.
  • “Kim Harris Jones is a tremendous addition to the Caesars Entertainment leadership team,” said Gary Carano, Executive Chairman of the Board, Caesars Entertainment.
  • “I’m pleased to count Kim Harris Jones among our Board of Directors,” said Tom Reeg, CEO of Caesars Entertainment.
  • With the addition of Harris Jones, Caesars Entertainment’s Board of Directors will grow to 10 members.

TrueBlue to Announce First Quarter 2024 Results

Retrieved on: 
星期一, 四月 22, 2024
Professional Services, Human Resources, Outsourcing Business, TBI, Webcast

TrueBlue (NYSE: TBI) will release first quarter 2024 earnings results after the market close on Monday, May 6, 2024.

Key Points: 
  • TrueBlue (NYSE: TBI) will release first quarter 2024 earnings results after the market close on Monday, May 6, 2024.
  • Management will discuss the results on a webcast at 2:00 p.m. PT (5:00 p.m.
  • ET) on Monday, May 6, 2024.
  • An audio replay will be available on the Company's website for a period of six months following the call.

TrueBlue's PeopleScout Announces Internal Appointments to its Executive Leadership Team

Retrieved on: 
星期三, 四月 24, 2024
Public sector, KPMG, Korn Ferry, TBI, RPO, Acquisition, Radancy, TrueBlue, Growth, Accenture, Management

Porter joined PeopleScout in 2018 as part of the company's acquisition of TMP Worldwide UK.

Key Points: 
  • Porter joined PeopleScout in 2018 as part of the company's acquisition of TMP Worldwide UK.
  • Joining Porter on the PeopleScout Executive Leadership team is Tim Powell, Managing Director, APAC, who will continue to lead the APAC operations for PeopleScout.
  • Prior to joining PeopleScout in 2022, Powell worked in key leadership roles with Deloitte, Accenture and Korn Ferry in APAC, Europe and North America.
  • "I look forward to welcoming Jon and Tim to our executive leadership team and benefitting from their wealth of experience and fresh perspectives.

Yeast Fuel, Developed by Chula's Faculty of Science Soon to Expand Its Production for the Aerospace Industry

Retrieved on: 
星期二, 四月 23, 2024
Cell, Cosmetics, Beer, Biomass, Culture, Chulalongkorn University, Food, Medicine, Petroleum, Soil, PTT Public Company Limited, Acetyl-CoA carboxylase, Plant, TBI, Biotechnology, GIEC, Hamburg University of Technology, University of Hamburg, Biological engineering, Safety, Health, Heat, Research, Transport, TUHH, Carbon, Dicarboxylic acid, Energy transformation, Human, Pressure, Faculty, Temperature, Bread, Acetyl-CoA, National Research Council, GRAS, Genetic engineering, Environment, Ministry, Aircraft, Fermentation, Drink, Growth, Air pollution

BANGKOK, April 23, 2024 /PRNewswire/ -- Yeast is a microorganism that is an important ingredient in many foods and beverages. However, in the future, yeast will play a major role in the production of fossil-based renewable fuels. 

Key Points: 
  • They aim to expand petroleum-based oil replacement production to reduce impacts on human health and the environment.
  • However, in the future, yeast will play a major role in the production of fossil-based renewable fuels.
  • Currently, researchers from Chulalongkorn University's Faculty of Science are accelerating their technological development to scale up the production of aviation biofuel from yeast.
  • Petroleum is an important source of fuel in today's world, both in various industrial sectors and in transportation, especially the aircraft industry.